Updated on 8 January 2016
Chugai Pharmaceutical Co Ltd has announced that Chugai and Novartis Pharma K K have agreed to terminate the agreement regarding co-marketing of aromatase inhibitor ‘Femara' tablets 2.5 mg (generic name: letrozole), a treatment for breast cancer after menopause in Japan, as of January 31, 2016.
Novartis Pharma will be solely responsible for the distribution and commercialization of Femara in Japan from February 1, 2016.
The companies indicate that both Chugai and Novartis Pharma will cooperate to accomplish a smooth transition. During the transition period, both companies will maintain the same level of product supply and adequate commercial activities to satisfy any medical needs.